Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy
Somatic and Visceral Analgesic Efficacy and Opioid-Sparing Effect of Ultrasound-Guided Intertransverse Process Block Versus Transversus Abdominis Plane Block After Robot, Laparoscopic Hepatectomy: A Randomized Controlled Trial
This prospective randomized controlled study will compare the postoperative analgesic efficacy and opioid-sparing effect of ultrasound-guided bilateral intertransverse process block (ITPB) with bilateral transversus abdominis plane (TAP) block combined with rectus sheath block in adults undergoing elective robotic or laparoscopic hepatectomy. A total of 64 participants will be randomly assigned in a 1:1 ratio to the ITPB group or the TAP block group. Both groups will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. The primary outcome is cumulative opioid consumption during the first 24 hours after surgery, expressed as intravenous morphine equivalents. Secondary outcomes include cumulative opioid consumption through 72 hours, incisional and visceral pain intensity, shoulder pain, sensory block distribution, rescue analgesic use, quality of recovery, postoperative recovery parameters, and adverse events.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Eligible adults scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia will be screened according to the predefined inclusion and exclusion criteria. After written informed consent is obtained, participants will receive preoperative education regarding pain assessment and patient-controlled analgesia and will complete the baseline Quality of Recovery-15 assessment.
On the day of surgery, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization sequence with allocation concealed using sealed opaque envelopes.
Before induction of general anesthesia, the assigned regional block will be performed under mild sedation and real-time ultrasound guidance by an experienced anesthesiologist. Participants assigned to the ITPB group will receive bilateral intertransverse process block at the T6-7 and T9-10 levels. Participants assigned to the comparator group will receive bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block.
Both groups will receive 0.3% ropivacaine at four injection sites, with 15 mL administered at each site, for a total volume of 60 mL and a total dose of 180 mg. In participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
Sensory block will be assessed using cold and pinprick testing at 5, 15, and 30 minutes after block placement. Participants, anesthesia and postoperative care providers, postoperative outcome assessors, and the statistical analyst will remain masked to treatment allocation. Because of the nature of the procedure, the anesthesiologist performing the assigned regional block cannot be masked and will not participate in subsequent postoperative management or outcome assessment.
All participants will receive standardized general anesthesia and multimodal postoperative analgesia, including patient-controlled analgesia. Postoperative outcomes will be assessed at 2, 4, 6, 12, 24, 48, and 72 hours after surgery and at discharge as applicable.
Blood samples will be collected at 35 minutes, 60 minutes, 90 minutes, 2 hours, 6 hours, and 25 hours after completion of the regional block.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Bon-Nyeo Koo, Professor
- 전화번호: +82-10-6208-5797
- 이메일: KOOBN@yuhs.ac
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Adults aged 19 years or older. American Society of Anesthesiologists physical status I-III. Scheduled for elective robotic or laparoscopic hepatectomy under general anesthesia.
Able to understand and use patient-controlled analgesia (PCA). Able to understand the purpose and procedures of the study and voluntarily provide written informed consent.
Exclusion Criteria:
History of allergy to local anesthetics or study medications. Coagulopathy, defined as INR > 1.5 or platelet count < 70,000/μL, or current anticoagulant use.
Infection at the regional block site. History of chronic pain or chronic opioid use for 3 months or longer. History of drug or alcohol abuse or dependence. Severe cardiopulmonary dysfunction or neurological disease. Cognitive impairment or psychiatric disease preventing cooperation with pain assessment, including the Numerical Rating Scale (NRS).
Body mass index (BMI) < 18 or > 35 kg/m². Pregnancy or breastfeeding. Scar at the block site that interferes with ultrasound visualization or local anesthetic spread.
History of abdominal surgery.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ITPB Group
Participants will receive ultrasound-guided bilateral intertransverse process block at the T6-7 and T9-10 levels before induction of general anesthesia. |
Before induction of general anesthesia and under mild sedation, bilateral intertransverse process block will be performed under real-time ultrasound guidance at the T6-7 and T9-10 levels. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
다른 이름들:
|
|
활성 비교기: TAP + Rectus Sheath Block Group
Participants will receive ultrasound-guided bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block before induction of general anesthesia. |
Before induction of general anesthesia and under mild sedation, bilateral oblique subcostal transversus abdominis plane block combined with rectus sheath block will be performed under real-time ultrasound guidance. Ropivacaine 0.3%, 15 mL, will be administered at each of four injection sites, for a total volume of 60 mL and a total dose of 180 mg. For participants weighing 60 kg or less, the total dose will be reduced to remain within 3 mg/kg.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cumulative Postoperative Opioid Consumption at 24 Hours
기간: From the end of surgery through 24 hours postoperatively
|
Cumulative opioid consumption during the first 24 hours after surgery will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents and summing the converted doses. |
From the end of surgery through 24 hours postoperatively
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cumulative Postoperative Opioid Consumption at Additional Time Points
기간: At 2, 4, 6, 12, 48, and 72 hours postoperatively.
|
Cumulative postoperative opioid consumption at each specified time point will be calculated by converting opioid doses administered through patient-controlled analgesia and rescue analgesia to intravenous morphine equivalents. |
At 2, 4, 6, 12, 48, and 72 hours postoperatively.
|
|
Incisional Pain Intensity
기간: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Incisional or somatic pain intensity will be assessed separately using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Visceral Pain Intensity
기간: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Deep or visceral abdominal pain intensity will be assessed separately using the Numeric Rating Scale (NRS). Participants will be instructed preoperatively to distinguish deep or generalized abdominal pain from pain at the incision site. |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Shoulder Pain Incidence and Intensity Assessed Using the Numeric Rating Scale (NRS)
기간: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
The presence of postoperative shoulder pain associated with diaphragmatic irritation will be recorded, and its intensity will be assessed using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Extent and Distribution of Sensory Block
기간: At 5, 15, and 30 minutes after completion of the regional block.
|
Sensory block will be assessed using cold and pinprick testing. The highest and lowest blocked dermatomes, the total number of blocked dermatomes, anterior and posterior spread, and the presence or absence of posterior/paravertebral sensory block will be recorded. |
At 5, 15, and 30 minutes after completion of the regional block.
|
|
Pain Intensity at Rest and During Coughing or Movement
기간: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
Pain intensity at rest and during coughing or movement will be assessed using the Numeric Rating Scale (NRS). |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Time to First Rescue Analgesic Request
기간: Up to 72 hours after surgery.
|
Time to the first request for rescue analgesia will be recorded. |
Up to 72 hours after surgery.
|
|
Frequency of Rescue Analgesic Administration
기간: During the first 48 hours postoperatively.
|
The number of rescue analgesic administrations during the first 48 postoperative hours will be recorded. |
During the first 48 hours postoperatively.
|
|
Quality of Recovery-15 (QoR-15) Score
기간: On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
|
Quality of recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire on postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21). |
On postoperative day 1, postoperative day 3, and at hospital discharge (between postoperative days 4 and 21).
|
|
Time to First Flatus
기간: From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
|
The time to first postoperative flatus will be recorded. |
From surgery until first postoperative flatus, assessed through postoperative day 3 (POD 3).
|
|
Time to First Ambulation
기간: From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
|
The time to first postoperative ambulation will be recorded. |
From surgery until first postoperative ambulation, assessed through postoperative day 3 (POD 3).
|
|
Postoperative Length of Hospital Stay
기간: From surgery through hospital discharge, an expected average of approximately 8 days.
|
Postoperative length of hospital stay will be recorded as the number of calendar days from the date of surgery to hospital discharge. The date of surgery will be defined as postoperative day (POD) 0. |
From surgery through hospital discharge, an expected average of approximately 8 days.
|
|
Opioid-Related Adverse Events
기간: At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
The incidence of opioid-related adverse events, including nausea, vomiting, excessive sedation, respiratory depression, pruritus, urinary retention, and reduced gastrointestinal motility, will be assessed. |
At 2, 4, 6, 12, 24, 48, and 72 hours postoperatively.
|
|
Block-Related Complications
기간: From regional block placement through 72 hours postoperatively.
|
The incidence of block-related complications, including pneumothorax, pleural puncture, hematoma, infection, local anesthetic systemic toxicity, nerve injury, lower-limb weakness, unintended neuraxial block, and intra-abdominal organ injury, will be assessed. |
From regional block placement through 72 hours postoperatively.
|
|
Comprehensive Complication Index (CCI)
기간: At hospital discharge, an expected average of approximately 8 days after surgery.
|
Postoperative complications will be assessed using the Comprehensive Complication Index (CCI) through hospital discharge. |
At hospital discharge, an expected average of approximately 8 days after surgery.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- 4-2026-1244
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .